Research Paper Volume 9, Issue 2 pp 547—555
Genetic polymorphisms (rs10636 and rs28366003) in metallothionein 2A increase breast cancer risk in Chinese Han population
- 1 Department of Oncology, Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, China
- 2 National Engineering Research Center for Miniaturized Detection Systems, School of Life Sciences, Northwest University, Xi’an 710069, China
Received: November 14, 2016 Accepted: February 9, 2017 Published: February 22, 2017
https://doi.org/10.18632/aging.101177How to Cite
Abstract
Genetic polymorphisms of MT2A are frequently observed in many different cancers. We performed this case-control study, including 459 breast cancer (BC) patients and 549 healthy controls from Northwest China, to evaluate the associations between two common MT2A polymorphisms (rs10636 and rs28366003) and BC risk. The MT2A polymorphisms were genotyped via Sequenom MassARRAY. The individuals with the rs28366003 A/G, A/G-G/G genotypes underwent a higher risk of BC (P<0.0001). And, the minor allele G of rs28366003 was related to an increased BC risk (P<0.0001). We also found a significantly increased BC risk with rs10636 polymorphism among homozygote and recessive models (P<0.05). Further subgroup analysis by clinical characteristics of BC patients showed that Scarff, Bloom and Richardson tumor grade (SBR) 1-2 have a higher expression of the minor allele of these two MT2A loci than SBR 3. Our results indicated that the rs10636 and rs28366003 polymorphisms in MT2A increased BC risk in Northwest Chinese Han population.
Introduction
Breast cancer (BC) is the most frequent cancer among women, expecting to be 252,710 new BC cases and 40,610 death cases among American women in 2017 [1]. And, the incidence of BC increased dramatically in Asian population in recent years [2]. It is widely known that genetic factors contribute to BC susceptibility [3–7]. Recent studies showed the expression of the Metallothionein 2A (MT2A) gene increased in some human neoplasms [8–10]. And, it has been reported that the high expression of MT2A associated with the stage and prognosis of tumors [9,11,12]. MT2 belongs to metallothioneins (MT), which have four groups (MT1, MT2, MT3 and MT4 proteins) and are encoded by a family of genes located on chromosome 16q13 [13].The expression of MT1 and MT2 are the most active isoforms in human cells [14]. And, the researchers found that MT1/MT2 may play an important role in tumors via several crucial mechanisms including modulating p53 zinc-dependent activity, inhibiting NF-κB signaling, and regulating the PIK3/AKT and Rb/E2F pathways [15–17]. The functional isoforms of MT2A mRNA transcript have been reported to express at the highest levels in breast tissues and is positively related to the cell proliferation and histological grade of BC [18].
Rs28366003 and rs10636 polymorphisms are the most common loci of MT2A, having been found to be associated with many different cancers. Rs28366003 locates in the core promoter region, while rs10636 polymorphism is in the 3’UTR region of the MT2A gene [17]. A recent study found that the single nucleotide polymorphism (SNP) rs28366003 stood apart from rs1610216 and rs10636 is significantly related to the laryngeal cancer risk in a Polish population [12]. Forma studied the association between MT2A (rs28366003, rs1610216, and rs10636) and the risk of prostate cancer. And only the rs28366003 SNP in MT2A was observed to be correlated with the prostate cancer risk in Polish population [19]. Similarly, Krzeslak’s data suggested that the rs28366003 polymorphism in MT2A was related to the BC risk in a Polish population [13]. Although several poly-morphisms have been identified in MT2A, the function of its polymorphisms in BC not being fully understood [20]. In this study, we investigated and comprehensive-ly assessed the association between two SNPs of MT2A (rs10636 and rs28366003) and BC risk in Chinese Han population.
Results
Characteristics of the study population
No significant difference was observed in the distribution of age, menopausal status, body mass index, and procreative times between the cases and controls (P>0.05), which suggested that the cases and controls of this study were matched adequately on general characteristics (Table 1). The genotypic frequencies of the MT2A rs10636 and rs28366003 polymorphisms among the controls were in accord with HWE (P = 0.343 and P = 0.363, respectively).
Table 1. The characteristics of breast cancer cases and cancer-free controls.
| Characteristics | Cases | Control | P value | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Number | 459 | 549 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Age (mean ± SD) | 49.09±11.02 | 48.80±8.28 | 0.61 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Age of menarche (mean ± SD) | 14.37±1.57 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Menopausal status | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Premenopausal | 237 | 267 | 0.376 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Postmenopausal | 222 | 282 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Body mass index (kg/m2) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| (mean ± SD) | 23.06±2.92 | 22.45±2.53 | 0.274 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Procreative times | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| <2 | 242 | 298 | 0.657 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ≥2 | 217 | 251 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumor size | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| <2 cm | 152 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ≥2 cm | 307 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Lymph node involvement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Negative | 184 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Positive | 275 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Histological grade | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| SBR 1-2 | 244 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| SBR 3 | 215 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Venous invasion | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| None–little | 292 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Moderate–severe | 167 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Immunohistochemistry results | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ER | – | 202 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| + | 257 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PR | – | 208 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| + | 251 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Her-2 | – | 330 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| + | 129 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ki67 | ≥ 14% | 294 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| < 14% | 165 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ER: Estrogen receptor; PR: Progesterone receptor; Her-2: human epidermal growth factor receptor 2; SBR: Scarff, Bloom and Richardson tumor grade | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
MT2A polymorphisms and the breast cancer risk
In terms of genotype and allele distributions of MT2A polymorphisms, two polymorphisms in MT2A (rs10636 and rs28366003) showed positive associations with BC risk (Table 2). Rs10636 was identified to increase the BC risk in codominant and recessive models (C/C vs. G/G: OR = 1.86, 95% CI: 1.17- 2.94, P = 0.008; C/C vs. G/G+G/C: OR = 1.96, 95% CI: 1.26- 3.05, P = 0.003). In addition, the rs28366003 polymorphism showed an association with BC risk in codominant, dominant, recessive and overdominant models ( A/G vs. A/A, OR = 2.29, 95%CI = 1.53-3.45, P < 0.0001; A/G+G/G vs. A/A, OR = 2.66, 95% CI = 1.78-3.96, P < 0.0001; A/G vs. A/A+G/G, OR = 2.23, 95% CI = 1.48-3.35, P < 0.0001). And, the minor allele G of rs28366993 was also related to increasing BC risk (G vs. A, OR = 2.87, 95% CI = 1.97-4.2, P < 0.0001).
Table 2. Association between MT2A polymorphisms (rs10636 and rs28366003) and breast cancer risk.
| Model | Genotype | Case(459) | Control(549) | OR (95% CI) | P-value | |
| rs10636 | HWE=0.343 | |||||
| Codominant | G/G | 241 (52.5%) | 290 (52.8%) | 1.00 | ||
| G/C | 164 (35.7%) | 224 (40.8%) | 0.88 (0.68-1.15) | 0.35 | ||
| C/C | 54 (11.8%) | 35 (6.4%) | 1.86 (1.17-2.94) | 0.008 | ||
| Dominant | G/G | 241 (52.5%) | 290 (52.8%) | 1.00 | ||
| G/C-C/C | 218 (47.5%) | 259 (47.2%) | 1.01 (0.79-1.30) | 0.92 | ||
| Recessive | G/G-G/C | 405 (88.2%) | 514 (93.6%) | 1.00 | ||
| C/C | 54 (11.8%) | 35 (6.4%) | 1.96 (1.26-3.05) | 0.003 | ||
| Overdominant | G/G-C/C | 295 (64.3%) | 325 (59.2%) | 1.00 | ||
| G/C | 164 (35.7%) | 224 (40.8%) | 0.81 (0.62-1.04) | 0.10 | ||
| Allele | G | 646 (%) | 804 (%) | 1.00 | ||
| C | 272 (%) | 294 (%) | 1.15 (0.95-1.40) | 0.16 | ||
| rs28366003 | HWE=0.363 | |||||
| Codominant | A/A | 378 (%) | 508 (%) | 1.00 | ||
| A/G | 70 (%) | 41 (%) | 2.29 (1.53-3.45) | <0.0001 | ||
| G/G | 11 (%) | 0 (%) | - | - | ||
| Dominant | A/A | 378 (%) | 508 (%) | 1.00 | ||
| A/G-G/G | 81 (%) | 41 (%) | 2.66 (1.78-3.96) | <0.0001 | ||
| Recessive | A/A-A/G | 447 (%) | 547 (%) | 1.00 | ||
| G/G | 11 (%) | 0 (%) | - | - | ||
| Overdominant | A/A-G/G | 390 (%) | 510 (%) | 1.00 | ||
| A/G | 70 (%) | 41 (%) | 2.23(1.48-3.35) | 0.0001 | ||
| Allele | A | 826 (%) | 1057 (%) | 1.00 | ||
| G | 92 (%) | 41 (%) | 2.87 (1.97-4.20) | <0.0001 | ||
MT 2A polymorphisms and the clinical features of breast cancer
We also analyzed the relationships between MT2A SNPs and clinical features of BC, including tumor size, lymph node metastasis, ER/PR/HER-2 status, his-tological grade, and venous invasion. As shown in Table 3, when the G/G genotype was used as a reference, there was no significant relation between the rs10636 polymorphism and clinical parameters except the histological grade (C/C vs. G/G: OR = 0.46, 95% CI = 0.29- 0.74, P = 0.001; G/C+C/C vs. G/G: OR = 0.63, 95% CI = 0.42- 0.93, P = 0.02). The same result was found in the analysis of the rs28366003 polymorphism and the histological grade of BC (G/G vs. A/A, OR = 0.52, 95% CI = 0.33- 0.82, P = 0.005, shown in Table 4).
Table 3. The associations between the MT-2A rs10636 polymorphism and clinical characteristics of BC patients.
| Variables | GG(%) | GC(%) | p | OR(95%CI) | CC(%) | p | OR(95%CI) | GC+CC (%) | p | OR(95%CI) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumor size | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| <2CM | 57(37.5) | 54(35.5) | 41(27) | 95(62.5) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ≥2CM | 98(31.9) | 104(33.9) | 0.63 | 1.12(0.71-1.78) | 105(34.2) | 0.11 | 1.49(0.92-2.42) | 209(68.1) | 0.23 | 1.2(0.85-1.92) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LN metastasis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Negative | 64(34.8) | 65(35.3) | 55(30) | 120(65.2) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Positive | 84(30.5) | 103(37.5) | 0.41 | 1.2(0.77-1.89) | 88(32) | 0.41 | 1.22(0.76-1.95) | 191(69.5) | 0.34 | 1.2(0.82-1.8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ER | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Negative | 77(38.1) | 63(31.2) | 62(30.7) | 125(61.9) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Positive | 79(30.4) | 91(35.4) | 0.135 | 1.41(0.9-2.21) | 87(33.9) | 0.174 | 1.3(0.87-2.15) | 178(69.3) | 0.1 | 1.3(0.94-2.05) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PR | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Negative | 90(43.3) | 96(46.2) | 22(10.5) | 118(56.7) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Positive | 111(44.2) | 106(42.2) | 0.58 | 0.90(0.61-1.33) | 34(13.5) | 0.46 | 1.25(0.69-2.29) | 140(55.8) | 0.84 | 0.96(0.66-1.39) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Her-2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Negative | 100(30.3) | 112(33.9) | 118(35.8) | 230(69.7) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Positive | 47(36.4) | 44(34.1) | 0.48 | 0.84(0.51-1.37) | 38(29.5) | 0.14 | 0.69(0.41-1.13) | 82(63.6) | 0.21 | 0.76(0.49-1.16) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ki-67 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ﹤50% | 80(27.2) | 85(28.9) | 129(43.9) | 214(72.8) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ≥50% | 42(25.5) | 47(28.5) | 0.84 | 1.05(0.63-1.77) | 76(46.1) | 0.63 | 1.12(0.7-1.79) | 123(74.5) | 0.68 | 1.1(0.71-1.69) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Histological grade | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| SBR 1-2 | 65(26.6) | 85(34.8) | 94(38.5) | 179(73.4) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| SBR 3 | 79(36.7) | 83(38.6) | 0.34 | 0.8(0.51-1.26) | 53(24.6) | 0.001 | 0.46(0.29-0.74) | 136(63.3) | 0.02 | 0.63(0.42-0.93) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Venous Invasion | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Non-little | 34(11.6) | 64(21.9) | 194(66.4) | 258(88.4) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Moderate-severe | 24(14.4) | 65(38.9) | 0.25 | 1.44(0.77-2.69) | 78(46.7) | 0.06 | 0.57(0.32-1.02) | 143(85.6) | 0.4 | 0.79(0.45-1.38) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LN: Axillary lymph node; ER: Estrogen receptor; PR: Progesterone receptor; Her-2: human epidermal growth factor receptor 2; SBR: Scarff, Bloom and Richardson tumor grade | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Table 4. The associations between the MT-2A rs28366003 polymorphism and clinical characteristics of BC patients.
| Variable | GG(%) | GC(%) | p | OR(95%CI) | CC(%) | p | OR(95%CI) | GC+CC (%) | p | OR(95%CI) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Tumor size | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| <2CM | 57(37.5) | 54(35.5) | 41(27) | 95(62.5) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ≥2CM | 98(31.9) | 104(33.9) | 0.63 | 1.12(0.71-1.78) | 105(34.2) | 0.11 | 1.49(0.92-2.42) | 209(68.1) | 0.23 | 1.14(0.74-1.75) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LN metastasis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Negative | 45(24.5) | 56(30.4) | 83(45.1) | 139(75.5) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Positive | 67(24.4) | 78(28.4) | 0.8 | 0.94(0.56-1.56) | 130(47.3) | 0.83 | 1.05(0.66-1.68) | 208(75.6) | 0.98 | 1.01(0.65-1.55) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ER | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Negative | 70(34.7) | 65(32.2) | 67(33.2) | 132(65.3) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Positive | 69(26.8) | 88(34.2) | 0.18 | 1.37(0.87-2.18) | 100(39) | 0.07 | 1.51(0.96-2.39) | 188(73.2) | 0.07 | 1.44(0.97-2.16) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| PR | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Negative | 55(26.4) | 67(32.2) | 86(41.3) | 153(73.6) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Positive | 77(30.7) | 81(32.2) | 0.54 | 0.86(0.54-1.39) | 93(37.1) | 0.26 | 0.77(0.49-1.22) | 174(69.3) | 0.32 | 0.81 (0.54-1.22) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Her-2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Negative | 71(21.5) | 82(24.8) | 177(53.6) | 259(78.5) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Positive | 35(27.1) | 33(25.6) | 0.49 | 0.82(0.46-1.45) | 61(47.3) | 0.16 | 0.7(0.43-1.15) | 94(72.9) | 0.2 | 0.74(0.46-1.18) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Ki-67 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| <14% | 44(145) | 105(35.7) | 145(49.3) | 250(85) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ≥14% | 27(16.3) | 64(38.8) | 0.98 | 0.99(0.56-1.76) | 74(44.8) | 0.52 | 0.83(0.48-1.45) | 138(83.6) | 0.69 | 0.9(0.53-1.52) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Histological grade | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| SBR 1-2 | 49(20) | 34(13.9) | 161(66) | 195(79.9) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| SBR 3 | 57(26.5) | 61(28.4) | 0.13 | 1.54(0.88-2.72) | 97(45.1) | 0.005 | 0.52(0.33-0.82) | 158(73.5) | 0.1 | 0.79(0.45-1.08) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Venous Invasion | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| None-little | 94(32.2) | 102(34.9) | 96(32.9) | 198(67.8) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Moderate-severe | 51(30.5) | 57(34.1) | 0.9 | 1.03(0.64-1.65) | 59(35.3) | 0.6 | 1.1(0.71-1.81) | 116(69.5) | 0.71 | 1.08(0.72-1.63) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| LN: Axillary lymph node; ER: Estrogen receptor; PR: Progesterone receptor; Her-2: human epidermal growth factor receptor 2; SBR: Scarff, Bloom and Richardson tumor grade | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Similarly, no significant correlation was detected between the rs28366003 polymorphism and other clinical features.
Discussion
It was reported that MT acts as a regulator in cell proliferation, apoptosis, and differentiation, which imply that MT may involve in carcinogenesis of BC [9,11,21–24]. The biological effects of MT are connected with its physiochemical properties [25,26]. Under the stress situation, MT regulates cell apoptosis, inhibits cell death and improves cell survival. Recent studies suggested the regulation of MT were completed by preventing oxidative progress and binding with apoptotic signal [27,28], in which MT could suppress free- radial- induced oxidative damage of tissues and cells.
The dysfunction of MT2A might be linked with the zinc release blockage and the reduction of intracellular zinc concentrations, which resulted in an increased risk of oxidative damage, as well as abnormal breast cells genesis [25]. As few studies concern to the relationship between the polymorphisms of MT2A and BC, we performed this case-control study in a Chinese population. Krzeslak, et al. have reported an association between rs28366003 polymorphism and the risk of ductal BC, prostate cancer, and laryngeal cancer in a Polish population [12,13,19]. We observed significant differences in genotypes distribution and allele frequencies of two MT2A gene polymorphisms locus (rs10636 and rs28366003) between BC patients and control groups (P < 0.05). The MT2A SNP rs28366003 is an A/G substitution that is situated in the core promoter region of the MT2A gene sequence between the TATA box and transcription initiation site [13]. The transition may reduce the binding to the core promoter region, which is a nuclear molecule regulates MT2A gene transcription [29]. In this way, MT2A SNPs might be associated with functional changes, which imply that they may be involved in the interactions with the behavior of BC cell. Finally, the biological features of BC cells are gradually influenced. In addition, MT2A rs10636 polymorphism is located in the 3’ untranslated region, which implies that it may be involved in interactions with other nucleotide polymorphisms [29]. Our results suggest that both of the two MT2A SNPs rs10636 and rs28366003 significantly influence the susceptibility of BC.
As indicated by Ki-67 immunohistochemistry, MT2A is related to the proliferation of BC [25]. And, the down-regulation of MT2A arrests growth in MCF-7 cell lines also suggested the involvement of MT2A in the proliferation of BC [29,30]. Moreover, it has been demonstrated that MT2A regulates endothelial cell migration through transcriptional regulation of the expression of vascular endothelial growth factor-c(VEGF-c) [31]. And it is believed that MT2A affects the histological differentiation grade in BC. The expression of MT2A mRNA in histological grade 3 tumors were higher than grade 1 and 2 tumors [20]. But in our study, BC patients with SBR 1-2 have a higher expression of the minor allele of MT2A SNPs loci than patients with SBR 3. So, we assume MT2A poly-morphisms may mitigate the aggressive behavior of BC cell. However, according to our results, there were no associations between ER/PR/HER-2 status, lymph node metastasis and MT2A polymorphisms (rs10636 and rs28366003)In terms of the current study limitations, the sample size was inadequate for a stratified analysis and analysis of mix-type BC. Besides, we did not investigate other predisposing factors, including high-dose radiation exposure, alcohol consumption, and postmenopausal obesity. The further study should assess these factors as well for a more precise evaluation.
In conclusion, this study showed that MT2A polymorphisms rs10636 and rs28366003 are associated with BC risk in Chinese Han population. And, the relationship of MT2A polymorphisms and the histological grade may guide us to judge prognosis of BC. Further functional studies and large population-based prospective studies are needed to provide accurate evidence about the influence of MT2A variants on BC.
Materials and Methods
Ethics statement
This study was approved by the Ethics Committee of the Second Affiliated Hospital of Xi’an Jiaotong university (Xi’an, China). The research protocol was completed according to the approved guidelines.
Subjects
The consent of all the participants was obtained after they were informed that their blood samples would be used for research purpose. The blood samples of 459 Chinese women with sporadic BC (mean age: 49.09 ± 11.02 years) were selected from the Second Affiliated Hospital of Xi’an Jiaotong University, Shaanxi Province, China. In addition, 549 age- and sex- matched healthy individuals (mean age: 48.80 ± 8.28 years) without any history of autoimmune or malignant diseases formed the control group. All of the BC cases and controls were Han population and from Northwest China. All the patients were diagnosed by histology or pathology, as described in our previous studies [32]. The data of clinicopatho-logical characteristics of patients, including tumor size, clinical stages, lymph node metastasis, menopausal status, procreative times, estrogen receptor (ER) status, progesterone receptor (PR) status, and human epidermal growth factor receptor type2 (HER-2) status, were obtained from the patients' medical records (Table 1).
DNA extraction and genotyping
The samples were contained in tubes coating with ethylene-diaminetetraacetic acid and were stored at −80°C after centrifugated until analysis. Genomic DNA was extracted from whole blood using the Universal Genomic DNA Extraction Kit Ver. 3.0 (TaKaRa Bio Inc., Shiga, Japan). DNA concentration was measured by spectrophotometry (DU530 UV/VIS spectro-photometer, Beckman Instruments, Fullerton, CA, USA). Two tag-SNPs (rs10636 and rs28366003) were selected in this study. A multiplexed SNP MassEXTEND assay was designed by Sequenom MassARRAY Assay Design 3.0 Software (Agena Bioscience, Inc., San Diego, CA, USA). SNP genotyping was performed by the Sequenom MassARRAY RS1000, and the primers were listed in Table 5. The data analyses were accomplished by Sequenom Type 4.0 [33].
Table 5. Primers used for this study.
| SNP_ID | 1st-PCRP | 2nd-PCRP | UEP_SEQ |
| rs10636 | ACGTTGGATGAGAACGCGACTTCCACAAAC | ACGTTGGATGCATAGAAAAAGGAATATAGC | GACGGAATATAGCAAACGGTCA |
| rs28366003 | GCCGCCTTACATCGCGGTTCAGGGAACTG | GAAGCAACCGCCCTTGGAGGAGGCGTGGT | AACTCAGGTCAACTGGATGCA |
Statistical analysis
All the statistical analyses were completed using the SPSS software package (version 20.0; SPSS Inc., Chicago, IL, USA). Hardy-Weinberg equilibrium (HWE) was examined by comparing expected and observed frequencies using Alrlquin 3.1 program (L. Excoffier, CMPG, University of Bern, Switzerland). The genotype frequencies of observed values were compared with expected values obtained from HWE theory (p2+2pq+q2=1; p is the frequency of the wild-type allele and q is the frequency of the variant allele). The calculation was performed by χ2 test and the degree of freedom was 1 in the cases and controls. The significant difference in allele and genotype frequencies between cases and controls was determined by Pearson's χ2 test [34,35]. And the cancer risk linked with alleles and genotypes was calculated with an odds ratio (OR) and 95% confidence interval (CI). We evaluated the risk in the codominant model (Aa vs. AA and aa vs. AA), dominant model (AA+ Aa vs. aa), recessive model (aa vs. Aa+AA), overdominant model (AA+ aa vs. Aa) and the allele model (a vs. A) respectively (A: the major allele, a: the minor allele). A two-sided P-value < 0.05 was considered statistically significant in all the tests.
Abbreviations
Conflicts of Interest
The authors have no conflict of interests to declare.
Funding
This work was supported by National Natural Science Foundation of China (No. 81471670/81274136); China Postdoctoral Science Foundation funded Projects (No. 2014M560791/2015T81037); the Fundamental Research Funds for the Central Universities, China (No.2014gjhz11); and the Funds of the Second Affiliated Hospital of Xi’an Jiaotong University for Young Scientists, China [YJ(QN)201305].
References
- 1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67:7–30. https://doi.org/10.3322/caac.21387 [PubMed]
- 2. Ghoncheh M, Momenimovahed Z, Salehiniya H. Epidemiology, Incidence and Mortality of Breast Cancer in Asia. Asian Pac J Cancer Prev. 2016; 17:47–52. [PubMed]
- 3. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, Wareham N, Ahmed S, Healey CS, et al, and SEARCH collaborators, and kConFab, and AOCS Management Group. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007; 447:1087–93. https://doi.org/10.1038/nature05887 [PubMed]
- 4. Wang X, Fredericksen ZS, Vierkant RA, Kosel ML, Pankratz VS, Cerhan JR, Justenhoven C, Brauch H, Olson JE, Couch FJ, and GENICA Consortium. Association of genetic variation in mitotic kinases with breast cancer risk. Breast Cancer Res Treat. 2010; 119:453–62. https://doi.org/10.1007/s10549-009-0404-3 [PubMed]
- 5. Cowper-Sal lari R, Zhang X, Wright JB, Bailey SD, Cole MD, Eeckhoute J, Moore JH, Lupien M. Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression. Nat Genet. 2012; 44:1191–98. https://doi.org/10.1038/ng.2416 [PubMed]
- 6. Ruark E, Snape K, Humburg P, Loveday C, Bajrami I, Brough R, Rodrigues DN, Renwick A, Seal S, Ramsay E, Duarte SV, Rivas MA, Warren-Perry M, et al, and Breast and Ovarian Cancer Susceptibility Collaboration, and Wellcome Trust Case Control Consortium. Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature. 2013; 493:406–10. https://doi.org/10.1038/nature11725 [PubMed]
- 7. Wang Y, Waters J, Leung ML, Unruh A, Roh W, Shi X, Chen K, Scheet P, Vattathil S, Liang H, Multani A, Zhang H, Zhao R, et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature. 2014; 512:155–60. https://doi.org/10.1038/nature13600 [PubMed]
- 8. Moleirinho A, Carneiro J, Matthiesen R, Silva RM, Amorim A, Azevedo L. Gains, losses and changes of function after gene duplication: study of the metallothionein family. PLoS One. 2011; 6:e18487. https://doi.org/10.1371/journal.pone.0018487 [PubMed]
- 9. Pan Y, Huang J, Xing R, Yin X, Cui J, Li W, Yu J, Lu Y. Metallothionein 2A inhibits NF-κB pathway activation and predicts clinical outcome segregated with TNM stage in gastric cancer patients following radical resection. J Transl Med. 2013; 11:173. https://doi.org/10.1186/1479-5876-11-173 [PubMed]
- 10. Nakane H, Hirano M, Ito H, Hosono S, Oze I, Matsuda F, Tanaka H, Matsuo K. Impact of metallothionein gene polymorphisms on the risk of lung cancer in a Japanese population. Mol Carcinog. 2015 (Suppl 1); 54:E122–28. https://doi.org/10.1002/mc.22198 [PubMed]
- 11. Pan YM, Xing R, Cui JT, Li WM, Lü YY. Clinicopathological significance of altered metallothionein 2A expression in gastric cancer according to Lauren’s classification. Chin Med J (Engl). 2013; 126:2681–86. [PubMed]
- 12. Starska K, Krześlak A, Forma E, Olszewski J, Lewy-Trenda I, Osuch-Wójcikiewicz E, Bryś M. Genetic polymorphism of metallothionein 2A and risk of laryngeal cancer in a Polish population. Med Oncol. 2014; 31:75. https://doi.org/10.1007/s12032-014-0075-8 [PubMed]
- 13. Krześlak A, Forma E, Jóźwiak P, Szymczyk A, Smolarz B, Romanowicz-Makowska H, Różański W, Bryś M. Metallothionein 2A genetic polymorphisms and risk of ductal breast cancer. Clin Exp Med. 2014; 14:107–13. https://doi.org/10.1007/s10238-012-0215-4 [PubMed]
- 14. Pedersen MO, Larsen A, Stoltenberg M, Penkowa M. The role of metallothionein in oncogenesis and cancer prognosis. Prog Histochem Cytochem. 2009; 44:29–64. https://doi.org/10.1016/j.proghi.2008.10.001 [PubMed]
- 15. Fu J, Lv H, Guan H, Ma X, Ji M, He N, Shi B, Hou P. Metallothionein 1G functions as a tumor suppressor in thyroid cancer through modulating the PI3K/Akt signaling pathway. BMC Cancer. 2013; 13:462. https://doi.org/10.1186/1471-2407-13-462 [PubMed]
- 16. Gumulec J, Balvan J, Sztalmachova M, Raudenska M, Dvorakova V, Knopfova L, Polanska H, Hudcova K, Ruttkay-Nedecky B, Babula P, Adam V, Kizek R, Stiborova M, Masarik M. Cisplatin-resistant prostate cancer model: differences in antioxidant system, apoptosis and cell cycle. Int J Oncol. 2014; 44:923–33. [PubMed]
- 17. Starska K, Bryś M, Forma E, Olszewski J, Pietkiewicz P, Lewy-Trenda I, Stasikowska-Kanicka O, Danilewicz M, Krześlak A. Metallothionein 2A core promoter region genetic polymorphism and its impact on the risk, tumor behavior, and recurrences of sinonasal inverted papilloma (Schneiderian papilloma). Tumour Biol. 2015; 36:8559–71. https://doi.org/10.1007/s13277-015-3616-7 [PubMed]
- 18. Rezk NA, Zidan HE, Riad M, Mansy W, Mohamad SA. Metallothionein 2A expression and its relation to different clinical stages and grades of breast cancer in Egyptian patients. Gene. 2015; 571:17–22. https://doi.org/10.1016/j.gene.2015.06.035 [PubMed]
- 19. Forma E, Krzeslak A, Wilkosz J, Jozwiak P, Szymczyk A, Rozanski W, Brys M. Metallothionein 2A genetic polymorphisms and risk of prostate cancer in a Polish population. Cancer Genet. 2012; 205:432–35. https://doi.org/10.1016/j.cancergen.2012.05.005 [PubMed]
- 20. Cherian MG, Jayasurya A, Bay BH. Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res. 2003; 533:201–09. https://doi.org/10.1016/j.mrfmmm.2003.07.013 [PubMed]
- 21. Dumańska M, Dziegiel P, Sopel M, Wojnar A, Zabel M. Evaluation of apoptosis, proliferation intensity and metallothionein (MT) expression in comparison with selected clinicopathological variables in primary adenocarcinomas of the large intestine. Folia Morphol (Warsz). 2004; 63:107–10. [PubMed]
- 22. Yang L, Li H, Yu T, Zhao H, Cherian MG, Cai L, Liu Y. Polymorphisms in metallothionein-1 and -2 genes associated with the risk of type 2 diabetes mellitus and its complications. Am J Physiol Endocrinol Metab. 2008; 294:E987–92. https://doi.org/10.1152/ajpendo.90234.2008 [PubMed]
- 23. Kim HG, Kim JY, Han EH, Hwang YP, Choi JH, Park BH, Jeong HG. Metallothionein-2A overexpression increases the expression of matrix metalloproteinase-9 and invasion of breast cancer cells. FEBS Lett. 2011; 585:421–28. https://doi.org/10.1016/j.febslet.2010.12.030 [PubMed]
- 24. Chen X, Lei L, Tian L, Zhu G, Jin T. Bone mineral density and polymorphisms in metallothionein 1A and 2A in a Chinese population exposed to cadmium. Sci Total Environ. 2012; 423:12–17. https://doi.org/10.1016/j.scitotenv.2012.02.020 [PubMed]
- 25. Jin R, Chow VT, Tan PH, Dheen ST, Duan W, Bay BH. Metallothionein 2A expression is associated with cell proliferation in breast cancer. Carcinogenesis. 2002; 23:81–86. https://doi.org/10.1093/carcin/23.1.81 [PubMed]
- 26. Bay BH, Jin R, Huang J, Tan PH. Metallothionein as a prognostic biomarker in breast cancer. Exp Biol Med (Maywood). 2006; 231:1516–21. https://doi.org/10.1177/153537020623100910 [PubMed]
- 27. Cai L, Klein JB, Kang YJ. Metallothionein inhibits peroxynitrite-induced DNA and lipoprotein damage. J Biol Chem. 2000; 275:38957–60. https://doi.org/10.1074/jbc.C000593200 [PubMed]
- 28. Shimoda R, Achanzar WE, Qu W, Nagamine T, Takagi H, Mori M, Waalkes MP. Metallothionein is a potential negative regulator of apoptosis. Toxicol Sci. 2003; 73:294–300. https://doi.org/10.1093/toxsci/kfg095 [PubMed]
- 29. Kita K, Miura N, Yoshida M, Yamazaki K, Ohkubo T, Imai Y, Naganuma A. Potential effect on cellular response to cadmium of a single-nucleotide A --> G polymorphism in the promoter of the human gene for metallothionein IIA. Hum Genet. 2006; 120:553–60. https://doi.org/10.1007/s00439-006-0238-6 [PubMed]
- 30. Lim D, Jocelyn KM, Yip GW, Bay BH. Silencing the Metallothionein-2A gene inhibits cell cycle progression from G1- to S-phase involving ATM and cdc25A signaling in breast cancer cells. Cancer Lett. 2009; 276:109–17. https://doi.org/10.1016/j.canlet.2008.10.038 [PubMed]
- 31. Schuermann A, Helker CS, Herzog W. Metallothionein 2 regulates endothelial cell migration through transcriptional regulation of vegfc expression. Angiogenesis. 2015; 18:463–75. https://doi.org/10.1007/s10456-015-9473-6 [PubMed]
- 32. Wang M, Wang Z, Wang XJ, Jin TB, Dai ZM, Kang HF, Guan HT, Ma XB, Liu XH, Dai ZJ. Distinct role of the Fas rs1800682 and FasL rs763110 polymorphisms in determining the risk of breast cancer among Han Chinese females. Drug Des Devel Ther. 2016; 10:2359–67. https://doi.org/10.2147/DDDT.S111084 [PubMed]
- 33. Gabriel S, Ziaugra L, Tabbaa D. SNP genotyping using the Sequenom MassARRAY iPLEX platform. Curr Protoc Hum Genet. 2009; Chapter 2: Unit 2 12.
- 34. Zhu J, Wang M, Zhu M, He J, Wang JC, Jin L, Wang XF, Xiang JQ, Wei Q. Associations of PI3KR1 and mTOR polymorphisms with esophageal squamous cell carcinoma risk and gene-environment interactions in Eastern Chinese populations. Sci Rep. 2015; 5:8250. https://doi.org/10.1038/srep08250 [PubMed]
- 35. Zhu J, Wang M, He J, Zhu M, Wang JC, Jin L, Wang XF, Yang YJ, Xiang JQ, Wei Q. Polymorphisms in the AKT1 and AKT2 genes and oesophageal squamous cell carcinoma risk in an Eastern Chinese population. J Cell Mol Med. 2016; 20:666–77. https://doi.org/10.1111/jcmm.12750 [PubMed]